Screening

BD Announces Industry-First CE Marked Assay for HPV Screening from At-Home Self-Collected Vaginal Samples

Retrieved on: 
Thursday, May 13, 2021
Cancer, Infectious causes of cancer, Clinical medicine, Gynaecological cancer, Medicine, Papillomavirus, Cancer screening, Cervical screening, Human papillomavirus infection, Cervical cancer, Screening

"\nAt-home collection will help address the urgent public health challenge of reaching women who do not attend routine cervical cancer screening.

Key Points: 
  • "\nAt-home collection will help address the urgent public health challenge of reaching women who do not attend routine cervical cancer screening.
  • "HPV self-sampling makes screening accessible to women who don\'t participate in screening or have limited access to screening.
  • The BD OnclarityHPV Assay has FDA approval for clinical use in cytology-based screening with ASC-US triage, in co-testing paradigm, and in primary HPV screening.
  • For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/ and Twitter @BDandCo .\n'

CREtelligent Announces New Suite of Environmental Screening Tools

Retrieved on: 
Tuesday, May 11, 2021
Spacecraft, Discovery Program, Geology of Mars, Insight, Screening, Mars, Spaceflight

b'SACRAMENTO, Calif., May 11, 2021 /PRNewswire/ -- CREtelligent.com today announced the addition of two new environmental screening tools to its suite of commercial real estate solutions.

Key Points: 
  • b'SACRAMENTO, Calif., May 11, 2021 /PRNewswire/ -- CREtelligent.com today announced the addition of two new environmental screening tools to its suite of commercial real estate solutions.
  • The EPS Pro Insight includes the risk rating, maps and database report but also provides a review and recommendations from a CREtelligent Environmental Professional to set the next course of action.
  • There may be no risky past NAICS codes, or maybe the property is in a very rural location," said Anthony Romano, CEO of CREtelligent.
  • "However, some require a deeper form of upfront screening to set the next best course of action.

Medscape's Public Health Group Launches CDC Colorectal Cancer Screening Provider Education Course

Retrieved on: 
Tuesday, May 11, 2021
Medicine, Health sciences, Medical terminology, Prevention, Infectious causes of cancer, Health, Cancer prevention, Colorectal cancer, Cancer, Screening, Preventive healthcare, Cervical screening

Jean Shapiro from CDC\'s Division of Cancer Prevention and Control explains, "Primary care providers can help ensure that patients receive appropriate colorectal cancer screening that can save lives.

Key Points: 
  • Jean Shapiro from CDC\'s Division of Cancer Prevention and Control explains, "Primary care providers can help ensure that patients receive appropriate colorectal cancer screening that can save lives.
  • These courses provide guidance for primary care providers on ways to improve the quality of colorectal cancer screening that their patients receive.
  • Dotson WD,et al.Stool-Based Colorectal Cancer Screening in the COVID-19 Era.
  • Five Things to Know About Colorectal Cancer Screening.

Whiterabbit, Creator of AI to Improve and Streamline Breast Cancer Diagnoses, Emerges from Stealth to Announce New CEO and FDA Clearance

Retrieved on: 
Tuesday, May 11, 2021
Medicine, Clinical medicine, Cancer screening, Health, Breast cancer screening, Breast cancer, Radiology, National Cancer Intelligence Network, Cancer, Screening, Mammography, Cultural differences in breast cancer diagnosis and treatment

This collaboration resulted in AI software that has been trained with decades-worth of breast cancer screening data.

Key Points: 
  • This collaboration resulted in AI software that has been trained with decades-worth of breast cancer screening data.
  • "\nWhiterabbit\'s executive team includes leading engineers, scientists, technologists, and world-class clinicians dedicated to advancing the process of breast cancer detection.
  • "\nWhiterabbit harnesses the power of data and artificial intelligence to improve the breast cancer screening process for radiologists and patients.
  • A growing number of radiologists and healthcare providers are using Whiterabbit\'s technology to improve patients\' experience with breast cancer screening.

World's First Health Security Company, TestZone, Partners With Leash IT To Bring Unparalleled Health Screening To The Workplace

Retrieved on: 
Monday, May 10, 2021
Safer, Screening

b'STAMFORD, Conn., May 10, 2021 /PRNewswire/ -- TestZone TM, a trusted provider of multi-layered health security solutions designed to make spaces safer, announces today a partnership with Melbourne, Australia-based Leash IT TM to utilize its LeashView platform, enhancing TestZone\'s onsite health security screening programs.

Key Points: 
  • b'STAMFORD, Conn., May 10, 2021 /PRNewswire/ -- TestZone TM, a trusted provider of multi-layered health security solutions designed to make spaces safer, announces today a partnership with Melbourne, Australia-based Leash IT TM to utilize its LeashView platform, enhancing TestZone\'s onsite health security screening programs.
  • It\'s never been more imperative we get people back to work in a safe, effective manner.
  • TestZone is very excited to partner with LeashView to significantly enhance our mission of making places safer," says David Orelowitz, co-founder and chief technology officer, TestZone.
  • Founded by a group of recognized leading experts in medical science and public health, TestZone creates customizable onsite solutions that combine screening, behavioral and IT systems to make spaces safer.

Promega, Exact Sciences Partnering to Help Jumpstart Colorectal Cancer Screenings

Retrieved on: 
Monday, May 10, 2021
Science, Research, Pharmaceutical, Oncology, Health, Genetics, Philanthropy, Fund Raising, Medicine, Colorectal cancer, Clinical medicine, Cancer, University of Wisconsin Carbone Cancer Center, Health, Screening

Colorectal cancer is the nation\xe2\x80\x99s No.

Key Points: 
  • Colorectal cancer is the nation\xe2\x80\x99s No.
  • 2 cancer killer, but it is up to 95% preventable with proper screening.
  • Money raised will go to UW Carbone Cancer Center programs aimed at increasing colon cancer screening and early detection.\nRegistration is open during the entire month of May at www.ColonCancerCoalition.org/Madison .
  • Event participation for colorectal cancer patients and survivors is free.

Major independent study shows Transpara® AI by ScreenPoint Medical can reduce radiologists' workload up to 70% for both 2D and 3D mammography

Retrieved on: 
Thursday, May 6, 2021
Medicine, Cancer screening, Clinical medicine, Breast imaging, Projectional radiography, Medical tests, Breast cancer, Tomosynthesis, X-ray computed tomography, Mammography, Screening, Radiology

The authors also found that using Transpara AI to transition from 2D to 3D mammography (digital breast tomosynthesis) screening would yield a 30% reduction in workload, a 25% improvement in sensitivity and a 27% reduction in the screening recall rate.

Key Points: 
  • The authors also found that using Transpara AI to transition from 2D to 3D mammography (digital breast tomosynthesis) screening would yield a 30% reduction in workload, a 25% improvement in sensitivity and a 27% reduction in the screening recall rate.
  • Furthermore, many countries are challenged with the backlog of diagnosed cancer cases due to Covid-19 screening delays.
  • The higher the number the higher the risk, enabling radiologists to focus on those women facing the highest risk.
  • This saving is so important as there is a global shortage of radiologists, with workload also on the increase due to the introduction of new imaging techniques such as 3D breast tomosynthesis."

Oncologists Sound the Alarm on Drop in Cancer Screenings

Retrieved on: 
Wednesday, May 5, 2021
Medicine, Clinical medicine, Medical specialties, Cancer screening, Prostate cancer, Histopathology, Cancer, Breast cancer, Proton therapy, Screening, Cancer prevention, Cancer survival rates

Experts recommend regular screenings for breast cancer, prostate cancer, cervical cancer, colorectal cancer, and lung cancer.\nA study published last fall in the JCO Clinical Cancer Informatics found an 85 percent drop in breast cancer screenings and a 74 percent decline in prostate cancer screenings.

Key Points: 
  • Experts recommend regular screenings for breast cancer, prostate cancer, cervical cancer, colorectal cancer, and lung cancer.\nA study published last fall in the JCO Clinical Cancer Informatics found an 85 percent drop in breast cancer screenings and a 74 percent decline in prostate cancer screenings.
  • "These screenings could help detect cancer at its earliest, most treatable stage.
  • "\nDetecting cancer in the early stages, before it spreads, could make patients eligible for a non-surgical treatment option called proton therapy.\nProCure is New Jersey\'s most experienced proton therapy Center.
  • "That means fewer side effects and a lower risk of life-threatening medical issues.

FlowPlay Launches In-Game Fundraiser to Remind Players Cancer Screening Saves Lives

Retrieved on: 
Monday, May 3, 2021
Medicine, Medical terminology, Prevention, Health, Cancer screening, Clinical medicine, Cancer, Screening, Breast cancer, American Cancer Society Cancer Action Network

Today, FlowPlay kicks off a new fundraiser to continue momentum for the ACS\'s work to fund cancer research, patient care and support those affected.

Key Points: 
  • Today, FlowPlay kicks off a new fundraiser to continue momentum for the ACS\'s work to fund cancer research, patient care and support those affected.
  • At the beginning of the pandemic, cancer screening rates decreased by nearly 90 percent for breast, cervical, colorectal, and lung cancer and recent reports indicate at least a 30 percent decline in the number of cancer screening tests being done compared to pre-pandemic years.
  • "\nThe ACS is working around the clock to prioritize preventive screening, cancer patient care, and also extend support to other vulnerable populations.
  • For more information, visit www.FlowPlay.com or contact [email protected] .\nThe American Cancer Society is a global grassroots force of 1.5 million volunteers dedicated to saving lives, celebrating lives, and leading the fight for a world without cancer.

AnPac Bio Announces Filing of Annual Report on Form 20-F for 2020

Medicine, Medical tests, Health, Clinical medicine, Cancer screening, Clinical Laboratory Improvement Amendments, Medical laboratory, Screening

b'SAN JOSE, Calif., April 30, 2021 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (NASDAQ: ANPC) (\xe2\x80\x9cAnPac Bio\xe2\x80\x9d or the \xe2\x80\x9cCompany\xe2\x80\x9d), a biotechnology company with operations in China and the United States focused on early cancer screening and detection, announced today that it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2020 with the U.S. Securities and Exchange Commission (the \xe2\x80\x9cSEC\xe2\x80\x9d) on April 30, 2021.\nThe Company\xe2\x80\x99s annual report on Form 20-F, which contains its audited consolidated financial statements, can be accessed on and downloaded from the SEC\xe2\x80\x99s website at www.sec.gov as well as on the Company\xe2\x80\x99s investor relations website at https://www.anpacbio.com .\nAnPac Bio is a biotechnology company focused on early cancer screening and detection, with 142 issued patents as of March 31, 2021.

Key Points: 
  • b'SAN JOSE, Calif., April 30, 2021 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (NASDAQ: ANPC) (\xe2\x80\x9cAnPac Bio\xe2\x80\x9d or the \xe2\x80\x9cCompany\xe2\x80\x9d), a biotechnology company with operations in China and the United States focused on early cancer screening and detection, announced today that it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2020 with the U.S. Securities and Exchange Commission (the \xe2\x80\x9cSEC\xe2\x80\x9d) on April 30, 2021.\nThe Company\xe2\x80\x99s annual report on Form 20-F, which contains its audited consolidated financial statements, can be accessed on and downloaded from the SEC\xe2\x80\x99s website at www.sec.gov as well as on the Company\xe2\x80\x99s investor relations website at https://www.anpacbio.com .\nAnPac Bio is a biotechnology company focused on early cancer screening and detection, with 142 issued patents as of March 31, 2021.
  • With two certified clinical laboratories in China and one CLIA and CAP accredited clinical laboratory and one CLIA registered clinical laboratory in the United States, AnPac Bio performs a suite of cancer screening and detection tests, including CDA (Cancer Differentiation Analysis), bio-chemical, immunological, and genomics tests.
  • According to Frost & Sullivan, AnPac Bio ranked third worldwide among companies offering next-generation early cancer screening and detection technologies in terms of the number of clinical samples for cancer screening and detection, based on approximately 41,700 clinical samples as of December 2019.
  • AnPac Bio\xe2\x80\x99s CDA technology platform has been shown in retrospective validation studies to be able to detect the risk of over 20 different cancer types with high sensitivity and specificity.\nFor investor and media inquiries, please contact:\n'